330 related articles for article (PubMed ID: 19636324)
1. Myopathy with statin-fibrate combination therapy: clinical considerations.
Jacobson TA
Nat Rev Endocrinol; 2009 Sep; 5(9):507-18. PubMed ID: 19636324
[TBL] [Abstract][Full Text] [Related]
2. Fibrates in combination with statins in the management of dyslipidemia.
Jacobson TA; Zimmerman FH
J Clin Hypertens (Greenwich); 2006 Jan; 8(1):35-41; quiz 42-3. PubMed ID: 16407687
[TBL] [Abstract][Full Text] [Related]
3. Fibrates are an essential part of modern anti-dyslipidemic arsenal: spotlight on atherogenic dyslipidemia and residual risk reduction.
Tenenbaum A; Fisman EZ
Cardiovasc Diabetol; 2012 Oct; 11():125. PubMed ID: 23057687
[TBL] [Abstract][Full Text] [Related]
4. Management of mixed dyslipidemia in patients with or at risk for cardiovascular disease: a role for combination fibrate therapy.
Fazio S
Clin Ther; 2008 Feb; 30(2):294-306. PubMed ID: 18343268
[TBL] [Abstract][Full Text] [Related]
5. "If it ain't broke, don't fix it": a commentary on the positive-negative results of the ACCORD Lipid study.
Tenenbaum A; Fisman EZ
Cardiovasc Diabetol; 2010 Jun; 9():24. PubMed ID: 20550659
[TBL] [Abstract][Full Text] [Related]
6. [Efficacy and safety of combined statin-fenofibrates therapy compared with monotherapy in patients with mixed hyperlipidemia and high risk of coronary heart disease].
Kłosiewicz-Latoszek L; Respondek W; Białobrzeska-Paluszkiewicz J; Grzybowska B; Jakóbisiak-Ostasz B; Stolarska I
Pol Merkur Lekarski; 2003 Jul; 15(85):42-6. PubMed ID: 14593958
[TBL] [Abstract][Full Text] [Related]
7. Does the addition of fibrates to statin therapy have a favorable risk to benefit ratio?
Brinton EA
Curr Atheroscler Rep; 2008 Feb; 10(1):25-32. PubMed ID: 18366982
[TBL] [Abstract][Full Text] [Related]
8. Fibrates after the FIELD study: Some answers, more questions.
Wierzbicki AS
Diab Vasc Dis Res; 2006 Dec; 3(3):166-71. PubMed ID: 17160911
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of fenofibric acid co-administered with low- or moderate-dose statin in patients with mixed dyslipidemia and type 2 diabetes mellitus: results of a pooled subgroup analysis from three randomized, controlled, double-blind trials.
Jones PH; Cusi K; Davidson MH; Kelly MT; Setze CM; Thakker K; Sleep DJ; Stolzenbach JC
Am J Cardiovasc Drugs; 2010; 10(2):73-84. PubMed ID: 20136164
[TBL] [Abstract][Full Text] [Related]
10. Statin-fibrate combination therapy.
Shek A; Ferrill MJ
Ann Pharmacother; 2001; 35(7-8):908-17. PubMed ID: 11485144
[TBL] [Abstract][Full Text] [Related]
11. Combination therapy of statins and fibrates in the management of cardiovascular risk.
Fiévet C; Staels B
Curr Opin Lipidol; 2009 Dec; 20(6):505-11. PubMed ID: 19829109
[TBL] [Abstract][Full Text] [Related]
12. Combined treatment with fibrates and small doses of atorvastatin in patients with mixed hyperlipidemia.
Liamis G; Kakafika A; Bairaktari E; Miltiadous G; Tsimihodimos V; Goudevenos J; Achimastos A; Elisaf M
Curr Med Res Opin; 2002; 18(3):125-8. PubMed ID: 12094821
[TBL] [Abstract][Full Text] [Related]
13. Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.
Nesto RW
Am J Cardiovasc Drugs; 2005; 5(6):379-87. PubMed ID: 16259526
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of fenofibric acid plus statins on multiple lipid parameters and its safety in women with mixed dyslipidemia.
Goldberg AC; Bittner V; Pepine CJ; Kelly MT; Thakker K; Setze CM; Lele A; Sleep DJ
Am J Cardiol; 2011 Mar; 107(6):898-905. PubMed ID: 21247520
[TBL] [Abstract][Full Text] [Related]
15. The role of a new formulation of fenofibric acid in the treatment of mixed dyslipidemia in type 2 diabetes.
Campbell J; Mohiuddin SM
Drugs Today (Barc); 2010 Oct; 46(10):757-64. PubMed ID: 21076712
[TBL] [Abstract][Full Text] [Related]
16. Fibrates: where are we now?
Seth Loomba R; Arora R
Ther Adv Cardiovasc Dis; 2009 Feb; 3(1):91-6. PubMed ID: 19144670
[TBL] [Abstract][Full Text] [Related]
17. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
Cziraky MJ; Watson KE; Talbert RL
J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
[TBL] [Abstract][Full Text] [Related]
18. Differential associations of statin and fibrate treatment with carotid arterial remodeling.
Chironi G; Simon A; Gariepy J; Balice M; Del-Pino M; Levenson J
Am J Hypertens; 2005 Nov; 18(11):1476-81. PubMed ID: 16280285
[TBL] [Abstract][Full Text] [Related]
19. Incidence of hospitalized rhabdomyolysis with statin and fibrate use in an insured US population.
Amend KL; Landon J; Thyagarajan V; Niemcryk S; McAfee A
Ann Pharmacother; 2011 Oct; 45(10):1230-9. PubMed ID: 21917557
[TBL] [Abstract][Full Text] [Related]
20. Optimal management of combined dyslipidemia: what have we behind statins monotherapy?
Tenenbaum A; Fisman EZ; Motro M; Adler Y
Adv Cardiol; 2008; 45():127-153. PubMed ID: 18230960
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
